MKI67 and breast carcinoma: A study by Cabrera-Galeana et al. [29] used Ki67 expression as a biomarker of molecular response to neoadjuvant chemotherapy in 435 patients and found that 57% (comprised of all different breast cancer subtypes) showed with a decrease in Ki67 expression and was correlated with better survival outcomes.